Advisory Panel To Consider Ischemic Colitis Warning For Zelnorm
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Gastrointestinal Drugs Advisory Committee will consider whether labeling for Novartis' irritable bowel disease therapy Zelnorm should contain a warning for ischemic colitis.
You may also be interested in...
Novartis' Zelnorm Efficacy Endpoint To Be Debated By FDA Advisory Cmte.
Novartis believes the endpoint captures qualitative aspects of a patient's chronic constipation. The agency also questioned whether the patients studied represent the indicated population.
Novartis Zelnorm Revised Labeling Includes Diarrhea Warning, Ischemic Colitis Precaution
The warning is the first in tegaserod labeling; Zelnorm was approved in 2002 without a warnings section. FDA has received 20 post-marketing reports of ischemic colitis; GSK’s Lotronex was withdrawn in 2000 following 49 reports.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.